Dafiro

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
11-11-2022
产品特点 产品特点 (SPC)
11-11-2022
公众评估报告 公众评估报告 (PAR)
10-07-2015

有效成分:

amlodipine, valsartan

可用日期:

Novartis Europharm Limited

ATC代码:

C09DB01

INN(国际名称):

amlodipine, valsartan

治疗组:

Agents acting on the renin-angiotensin system

治疗领域:

Hypertension

疗效迹象:

Treatment of essential hypertension. Dafiro is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,

產品總結:

Revision: 30

授权状态:

Authorised

授权日期:

2007-01-15

资料单张

                                51
B. PACKAGE LEAFLET
52
PACKAGE LEAFLET: INFORMATION FOR THE USER
DAFIRO 5 MG/80 MG FILM-COATED TABLETS
DAFIRO 5 MG/160 MG FILM-COATED TABLETS
DAFIRO 10 MG/160 MG FILM-COATED TABLETS
amlodipine/valsartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
-
WHAT IS IN THIS LEAFLET
1.
What Dafiro is and what it is used for
2.
What you need to know before you take Dafiro
3.
How to take Dafiro
4.
Possible side effects
5.
How to store Dafiro
6.
Contents of the pack and other information
1.
WHAT DAFIRO IS AND WHAT IT IS USED FOR
Dafiro tablets contain two substances called amlodipine and valsartan.
Both of these substances help
to control high blood pressure.
−
Amlodipine belongs to a group of substances called “calcium channel
blockers”. Amlodipine
stops calcium from moving into the blood vessel wall which stops the
blood vessels from
tightening.
−
Valsartan belongs to a group of substances called “angiotensin-II
receptor antagonists”.
Angiotensin II is produced by the body and makes the blood vessels
tighten, thus increasing the
blood pressure. Valsartan works by blocking the effect of angiotensin
II.
This means that both of these substances help to stop the blood
vessels tightening. As a result, the
blood vessels relax and blood pressure is lowered.
Dafiro is used to treat high blood pressure in adults whose blood
pressure is not controlled enough
with either amlodipine or valsartan on its own.
53
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DAFIRO
DO NOT TAKE DAFIRO
−
if you are allergic to amlodipine or to any other cal
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Dafiro 5 mg/80 mg film-coated tablets
Dafiro 5 mg/160 mg film-coated tablets
Dafiro 10 mg/160 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Dafiro 5 mg/80 mg film-coated tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besylate) and 80 mg of valsartan.
Dafiro 5 mg/160 mg film-coated tablets
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine
besylate) and 160 mg of valsartan.
Dafiro 10 mg/160 mg film-coated tablets
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine
besylate) and 160 mg of
valsartan.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
Dafiro 5 mg/80 mg film-coated tablets
Dark yellow, round film-coated tablet with bevelled edges, imprinted
with “NVR” on one side and
“NV” on the other side. Approximate size: diameter 8.20 mm.
Dafiro 5 mg/160 mg film-coated tablets
Dark yellow, oval film-coated tablet, imprinted with “NVR” on one
side and “ECE” on the other side.
Approximate size: 14.2 mm (length) x 5.7 mm (width).
Dafiro 10 mg/160 mg film-coated tablets
Light yellow, oval film-coated tablet, imprinted with “NVR” on one
side and “UIC” on the other side.
Approximate size: 14.2 mm (length) x 5.7 mm (width).
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension.
Dafiro is indicated in adults whose blood pressure is not adequately
controlled on amlodipine or
valsartan monotherapy.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose of Dafiro is one tablet per day.
Dafiro 5 mg/80 mg may be administered in patients whose blood pressure
is not adequately controlled
with amlodipine 5 mg or valsartan 80 mg alone.
Dafiro 5 mg/160 mg may be administered in patients whose blood
pressure is not adequately
controlled with amlodipine 5 mg or valsartan 160 mg alone.
Dafiro 10 mg/160 mg may be administered in patients whose blood
pressure is 
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 11-11-2022
产品特点 产品特点 保加利亚文 11-11-2022
公众评估报告 公众评估报告 保加利亚文 10-07-2015
资料单张 资料单张 西班牙文 11-11-2022
产品特点 产品特点 西班牙文 11-11-2022
公众评估报告 公众评估报告 西班牙文 10-07-2015
资料单张 资料单张 捷克文 11-11-2022
产品特点 产品特点 捷克文 11-11-2022
公众评估报告 公众评估报告 捷克文 10-07-2015
资料单张 资料单张 丹麦文 11-11-2022
产品特点 产品特点 丹麦文 11-11-2022
公众评估报告 公众评估报告 丹麦文 10-07-2015
资料单张 资料单张 德文 11-11-2022
产品特点 产品特点 德文 11-11-2022
公众评估报告 公众评估报告 德文 10-07-2015
资料单张 资料单张 爱沙尼亚文 11-11-2022
产品特点 产品特点 爱沙尼亚文 11-11-2022
公众评估报告 公众评估报告 爱沙尼亚文 10-07-2015
资料单张 资料单张 希腊文 11-11-2022
产品特点 产品特点 希腊文 11-11-2022
公众评估报告 公众评估报告 希腊文 10-07-2015
资料单张 资料单张 法文 11-11-2022
产品特点 产品特点 法文 11-11-2022
公众评估报告 公众评估报告 法文 10-07-2015
资料单张 资料单张 意大利文 11-11-2022
产品特点 产品特点 意大利文 11-11-2022
公众评估报告 公众评估报告 意大利文 10-07-2015
资料单张 资料单张 拉脱维亚文 11-11-2022
产品特点 产品特点 拉脱维亚文 11-11-2022
公众评估报告 公众评估报告 拉脱维亚文 10-07-2015
资料单张 资料单张 立陶宛文 11-11-2022
产品特点 产品特点 立陶宛文 11-11-2022
公众评估报告 公众评估报告 立陶宛文 10-07-2015
资料单张 资料单张 匈牙利文 11-11-2022
产品特点 产品特点 匈牙利文 11-11-2022
公众评估报告 公众评估报告 匈牙利文 10-07-2015
资料单张 资料单张 马耳他文 11-11-2022
产品特点 产品特点 马耳他文 11-11-2022
公众评估报告 公众评估报告 马耳他文 10-07-2015
资料单张 资料单张 荷兰文 11-11-2022
产品特点 产品特点 荷兰文 11-11-2022
公众评估报告 公众评估报告 荷兰文 10-07-2015
资料单张 资料单张 波兰文 11-11-2022
产品特点 产品特点 波兰文 11-11-2022
公众评估报告 公众评估报告 波兰文 10-07-2015
资料单张 资料单张 葡萄牙文 11-11-2022
产品特点 产品特点 葡萄牙文 11-11-2022
公众评估报告 公众评估报告 葡萄牙文 10-07-2015
资料单张 资料单张 罗马尼亚文 11-11-2022
产品特点 产品特点 罗马尼亚文 11-11-2022
公众评估报告 公众评估报告 罗马尼亚文 10-07-2015
资料单张 资料单张 斯洛伐克文 11-11-2022
产品特点 产品特点 斯洛伐克文 11-11-2022
公众评估报告 公众评估报告 斯洛伐克文 10-07-2015
资料单张 资料单张 斯洛文尼亚文 11-11-2022
产品特点 产品特点 斯洛文尼亚文 11-11-2022
公众评估报告 公众评估报告 斯洛文尼亚文 10-07-2015
资料单张 资料单张 芬兰文 11-11-2022
产品特点 产品特点 芬兰文 11-11-2022
公众评估报告 公众评估报告 芬兰文 10-07-2015
资料单张 资料单张 瑞典文 11-11-2022
产品特点 产品特点 瑞典文 11-11-2022
公众评估报告 公众评估报告 瑞典文 10-07-2015
资料单张 资料单张 挪威文 11-11-2022
产品特点 产品特点 挪威文 11-11-2022
资料单张 资料单张 冰岛文 11-11-2022
产品特点 产品特点 冰岛文 11-11-2022
资料单张 资料单张 克罗地亚文 11-11-2022
产品特点 产品特点 克罗地亚文 11-11-2022
公众评估报告 公众评估报告 克罗地亚文 10-07-2015

搜索与此产品相关的警报

查看文件历史